Hurley Capital
RARE icon

Hurley Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Hurley Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.06K Hold
137
– – ﹤0.01% 545
2026
Q2 		$4.57K Hold
137
– – ﹤0.01% 456
2026
Q1 		$2.87K Hold
137
– – ﹤0.01% 538
2025
Q4 		$3.15K Buy
+137
New +$4.5K ﹤0.01% 483

Other funds holding RARE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Hurley Capital's RARE Position: Q3 2026 in Review

Hurley Capital held its Ultragenyx Pharmaceutical (RARE) position steady in Q3 2026 at 137 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #545.

Hurley Capital first reported a position in RARE in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.57K in Q2 2026. 91 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Hurley Capital held 137 shares of Ultragenyx Pharmaceutical worth $2.06K as of Q3 2026.
  • Hurley Capital left its Ultragenyx Pharmaceutical share count unchanged in Q3 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #545 holding.
  • Hurley Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 4 quarters since.
  • Hurley Capital's Ultragenyx Pharmaceutical position peaked at $4.57K in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.